Online citations, reference lists, and bibliographies.

Proton-pump Inhibitor Use Is Not Associated With Osteoporosis Or Accelerated Bone Mineral Density Loss.

L. Targownik, L. Lix, S. Leung, W. Leslie
Published 2010 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUNDS & AIMS Recent studies have shown an association between proton-pump inhibitor use (PPI) and hip fracture. The mechanism by which PPI use promotes the development of hip fracture is uncharacterized. Therefore, we sought to determine whether PPI use is associated with osteoporosis or accelerated bone mineral density (BMD) loss. METHODS We used the Manitoba Bone Mineral Density Database to determine the relationship between chronic PPI use and osteoporosis on an initial assessment of BMD and on BMD loss between successive assessments of BMD. In the cross-sectional study, cases with osteoporosis at the hip or lumbar vertebrae (T-score < or =-2.5) were matched to 3 controls with normal BMD (T-score > or =-1.0). In the longitudinal analysis, the change in BMD among PPI users and nonusers between successive BMD assessments was assessed. Conditional logistic regression and multivariate linear regression were used to obtain estimates of the association between PPI use and osteoporosis and of the annualized change in BMD associated with PPI use. RESULTS PPI use was not associated with having osteoporosis at either the hip (OR, 0.84; 95% CI, 0.55-1.34) or the lumbar spine (OR, 0.79; 95% CI, 0.59-1.06) for PPI use >1500 doses over the previous 5 years. In the longitudinal study no significant decrease was observed in BMD at either site attributable to PPI use. CONCLUSIONS PPI use does not appear to be associated with either the presence of osteoporosis or accelerated BMD loss. The association between PPI use and hip fracture is probably related to factors independent of osteoporosis.
This paper references
Proton pumpinhibiting drugs , calcium homeostasis , and bone health
MJ Wright (1985)
10.1007/BF00294730
Calcium/phosphate/vitamin D homeostasis and bone mass in patients after gastrectomy, vagotomy, and cholecystectomy
Ewa Marcinowska-Suchowierska (1995)
10.1016/j.bone.2003.10.001
Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study.
S. C. Schuit (2004)
10.1080/003655201750422585
Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats.
G L Cui (2001)
10.1016/j.bone.2006.02.002
The importance of spectrum bias on bone density monitoring in clinical practice.
W. Leslie (2006)
10.1359/jbmr.2003.18.11.1947
BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures.
K. Stone (2003)
10.1111/j.1572-0241.2007.01106.x
The Prevalence of and the Clinical and Demographic Characteristics Associated With High-Intensity Proton Pump Inhibitor Use
Laura E Targownik (2007)
10.1056/nejm198512053132319
Calcium absorption and achlorhydria.
Robert Roy Recker (1985)
10.1210/jc.2004-1568
Hip fracture in women without osteoporosis.
Stacey A Wainwright (2005)
Study of Osteoporotic Fractures Research Group
K. Ensrud (1997)
10.1172/JCI111254
An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium.
G. Bo-Linn (1984)
10.3109/00365529409092460
Growth of the parathyroid glands in omeprazole-treated chickens.
Rebecca Gagnemo-Persson (1994)
Establishing a population databased policy unit
NP Roos (1999)
10.3109/00365527709181713
The parathyroid glands in experimentally induced hypergastrinemia in the rat.
Lars Grimelius (1977)
10.1016/j.abb.2008.03.025
Function, structure and regulation of the vacuolar (H+)-ATPases.
Kevin C. Jefferies (2008)
10.1001/archinte.1997.00440290041004
Weight Change and Fractures in Older Women
Kristine E Ensrud (1997)
10.1001/archinte.167.12.1246
Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men.
E. Haney (2007)
10.1016/0375-9474(83)90702-9
Highlights of the conference
Walter Greiner (1983)
10.1016/S0378-5122(97)88484-8
Mortality following fractures in older women. The study of osteoporotic fractures.
Warren S. Browner (1996)
10.1359/jbmr.2001.16.3.581
Use of oral corticosteroids and risk of fractures.
T. V. van Staa (2000)
Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system.
N. Roos (1999)
10.7326/0003-4819-129-2-199807150-00002
Physical Activity and Osteoporotic Fracture Risk in Older Women
E. Gregg (1998)
10.1053/gast.2003.50106
AGA technical review on osteoporosis in gastrointestinal diseases.
Charles N. Bernstein (2003)
10.1359/jbmr.1997.12.11.1761
Prevalence of low femoral bone density in older U.S. adults from NHANES III.
A. Looker (1997)
10.1016/j.bone.2006.11.008
Clinical risk factors for fracture in postmenopausal Canadian women: a population-based prevalence study.
W. Leslie (2007)
10.1001/jama.285.21.2736
Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk-adjusted hospital outcomes.
Edward L. Hannan (2001)
10.1016/j.bone.2008.06.001
Validation of ten-year fracture risk prediction: a clinical cohort study from the Manitoba Bone Density Program.
W. Leslie (2008)
10.1016/S0016-5085(09)60316-4
414 Proton Pump Inhibitors, H2 Antagonists, and Risk of Hip Fracture: A Large Population-Based Study
Douglas A. Corley (2009)
10.1053/j.gastro.2008.01.010
The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
L. Targownik (2008)
10.1111/j.1753-4887.2008.00015.x
Proton pump-inhibiting drugs, calcium homeostasis, and bone health.
M. Wright (2008)
10.1001/jama.296.24.2947
Long-term proton pump inhibitor therapy and risk of hip fracture.
Yu-Xiao Yang (2006)
10.1592/phco.28.8.951
Proton pump inhibitor use and risk of hip fractures in patients without major risk factors.
James A Kaye (2008)
10.7326/0003-4819-133-10-200011210-00012
The Incidence of Fracture among Patients with Inflammatory Bowel Disease: A Population-Based Cohort Study
C. Bernstein (2000)
10.1016/j.bone.2007.11.001
A reference standard for the description of osteoporosis.
J. Kanis (2008)
10.1038/ncprheum0798
Technology Insight: noninvasive assessment of bone strength in osteoporosis
M. Bouxsein (2008)
Proton pump inhibitors , H 2 antagonists , and risk of hip fracture : a large population - based study
DA Corley (2006)
10.1385/JCD:8:1:025
Construction and validation of a population-based bone densitometry database.
W. Leslie (2005)
10.1056/NEJM199503233321202
Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.
Steve R. Cummings (1995)
10.1007/s00223-008-9170-1
Acid-Suppressive Medications and Risk of Bone Loss and Fracture in Older Adults
Elaine W Yu (2008)
10.1007/s00223-006-0021-7
Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture
P. Vestergaard (2006)
10.1503/cmaj.071330
Use of proton pump inhibitors and risk of osteoporosis-related fractures
L. Targownik (2008)
10.1007/s00198-004-1622-5
Health-related quality of life after osteoporotic fractures
Inger Hallberg (2004)
10.1001/archinte.157.8.857
Weight change and fractures in older women. Study of Osteoporotic Fractures Research Group.
Kristine E Ensrud (1997)
10.1093/rheumatology/ken180
Advanced CT bone imaging in osteoporosis
Harry K. Genant (2008)
10.1097/00004424-199001000-00004
Predicting femoral neck strength from bone mineral data. A structural approach.
Thomas J. Beck (1990)
10.1097/00005650-199906001-00006
Establishing a population data-based policy unit.
N. Roos (1999)
Use of proton pump inhibitors and risk of osteoporosisrelated fractures
LE Targownik (2008)
Clinical risk factors for fracture in postmenopausal Canadian women : a populationbased prevalence study
WD Leslie (2008)
10.1080/07315724.2000.10718083
The Bioavailability of Dietary Calcium
L. Guéguen (2000)



This paper is referenced by
10.1016/j.gtc.2010.08.009
The safety of drugs used in acid-related disorders and functional gastrointestinal disorders.
Neehar D. Parikh (2010)
10.1016/j.giec.2019.12.005
Proton Pump Inhibitors: The Good, Bad, and Ugly.
Felice H Schnoll-Sussman (2020)
10.1016/j.cgh.2012.11.031
Reported side effects and complications of long-term proton pump inhibitor use: dissecting the evidence.
David Alan Johnson (2013)
10.1016/j.ebiom.2015.11.024
Lansoprazole Upregulates Polyubiquitination of the TNF Receptor-Associated Factor 6 and Facilitates Runx2-mediated Osteoblastogenesis
Kenichi Mishima (2015)
10.1007/s00198-013-2352-3
Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population-based cohort study
S. Majumdar (2013)
10.1002/jbmr.2344
Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.
Daniel H. Solomon (2015)
10.21019/9781582122250.CH13
Chapter 13: Heartburn and Dyspepsia
T. Whetsel (2015)
10.1007/s00198-010-1337-8
Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study
Sander Pouwels (2010)
10.1053/j.seminhematol.2011.10.006
Gastrointestinal, hepatobiliary, pancreatic, and iron-related diseases in long-term survivors of allogeneic hematopoietic cell transplantation.
Aiko Kida (2012)
10.1007/s41970-019-00095-5
Protonenpumpeninhibitoren und Osteoporoserisiko
Rudolf Wolfgang Gasser (2020)
10.1097/SMJ.0b013e31826efbea
Proton Pump Inhibitors: The Good, the Bad, and the Unwanted
Saman Chubineh (2012)
10.1007/s00223-014-9855-6
The Relationship Between Proton Pump Inhibitor Adherence and Fracture Risk in the Elderly
Jian Ding (2014)
10.1007/978-3-030-27592-1
Foregut Surgery: Achalasia, Gastroesophageal Reflux Disease and Obesity
Marco G Patti (2020)
Gastroesophageal reflux disease: endoscopy, duration of treatment, and choice of PPI.
Neil R Greenspan (2011)
10.1007/978-1-60327-542-2_20
Gastric Acid Secretions, Treatments, and Nutritional Consequences
Ronit Zilberboim (2010)
10.1002/PHAR.1007
Fracture risk and bone mineral density reduction associated with proton pump inhibitors.
Yuen Ting Lau (2012)
10.1097/MCG.0b013e3182333820
Recent safety concerns with proton pump inhibitors.
Joan Chen (2012)
10.1016/j.dld.2016.05.018
Are proton pump inhibitors really so dangerous?
Vincenzo Savarino (2016)
Bone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysis.
Sidong Yang (2015)
10.1002/lio2.187
Proton pump inhibitors: Review of reported risks and controversies
Simon Brisebois (2018)
10.1016/J.JOMH.2011.01.002
Osteoporosis in men
Gretchen M. Dickson (2011)
10.1001/jama.2011.626
Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial.
Jean Paul Galmiche (2011)
10.1016/B978-1-4377-2333-5.00027-4
Biomarkers for Stool Analysis
Andrea Girman (2013)
10.1007/s11938-014-0030-y
Proton Pump Inhibitors and Risk of Bone Fractures
G. Leontiadis (2014)
Medical therapy of GERD and NERD The severity of symptoms does not correlate with the presence or with severity of subtypes of GERD (
Smout AJPM (2012)
10.1007/s11938-017-0115-5
Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors
Felice Schnoll-Sussman (2017)
10.1097/MOG.0b013e32833ea9d9
Adverse effects of proton pump inhibitor drugs: clues and conclusions
D. M. Mccarthy (2010)
10.1016/j.bone.2013.09.014
Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals.
Marcello Maggio (2013)
10.1007/s12603-015-0512-1
Association of Proton Pump Inhibitor Use with Recurrent Falls and Risk of Fractures in Older Women: A Study of Medication Use in Older Fallers.
Heinrich Wolfgang Thaler (2016)
10.1038/ajg.2016.481
Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure
L. Targownik (2017)
10.1007/s00296-018-4142-x
Proton pump inhibitors’ use and risk of hip fracture: a systematic review and meta-analysis
Salman Hussain (2018)
Clinical Practice Guideline For the Diagnosis and Management of Gastroesophageal Reflux Disease
Philip O Katz (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar